ATAI vs. ARQT, AMPH, IMCR, AAPG, KNSA, DYN, GPCR, ARDX, INDV, and NRIX
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Indivior (INDV), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.
Atai Life Sciences vs.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Atai Life Sciences has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atai Life Sciences had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 6 mentions for Atai Life Sciences and 3 mentions for Arcutis Biotherapeutics. Atai Life Sciences' average media sentiment score of 0.80 beat Arcutis Biotherapeutics' score of 0.25 indicating that Atai Life Sciences is being referred to more favorably in the news media.
28.4% of Atai Life Sciences shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Arcutis Biotherapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.
Atai Life Sciences received 270 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 66.47% of users gave Atai Life Sciences an outperform vote while only 65.63% of users gave Arcutis Biotherapeutics an outperform vote.
Arcutis Biotherapeutics presently has a consensus price target of $16.60, indicating a potential upside of 27.50%. Atai Life Sciences has a consensus price target of $9.00, indicating a potential upside of 352.26%. Given Atai Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Atai Life Sciences is more favorable than Arcutis Biotherapeutics.
Atai Life Sciences has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Atai Life Sciences' return on equity of -65.75% beat Arcutis Biotherapeutics' return on equity.
Summary
Atai Life Sciences beats Arcutis Biotherapeutics on 14 of the 18 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATAI) was last updated on 2/22/2025 by MarketBeat.com Staff
